false
0001157075
0001157075
2026-11-15
2026-11-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of
earliest event reported): November 15,
2026
PHARMACYTE
BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
| Nevada |
001-40699 |
62-1772151 |
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
3960
Howard Hughes Parkway, Suite
500 Las
Vegas,
Nevada |
89169 |
| (Address of Principal Executive Offices) |
(Zip Code) |
Registrant's telephone number, including area code:
(917) 595-2850
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of exchange on which registered |
| Common Stock, Par Value $0.0001 Per Share |
|
PMCB |
|
The Nasdaq
Stock Market LLC |
| |
|
|
|
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive
Agreement.
Consent and Warrant Exchange Agreement
On November 15, 2026, PharmaCyte
Biotech, Inc. (the “Company”) entered into a Consent and Warrant Exchange Agreement (the “Warrant Exchange Agreement”)
with Q/C Technologies, Inc., formerly known as TNF Pharmaceuticals, Inc. (“Q/C”). Under the Warrant Exchange Agreement, the
Company agreed to exchange 851,304 Series G Long-Term Warrants to purchase shares of Q/C’s common stock, par value $0.001 per share
(the “Q/C Common Stock”), held by the Company, which were issued pursuant to that certain Securities Purchase Agreement, dated
May 20, 2024, by and among Q/C and the purchasers party thereto, including the Company (such exchanged warrants, the “Exchange Warrants”),
for an aggregate of 4,982,272 shares of Q/C Common Stock (the “Exchange Shares”) (the “Warrant Exchange”). The
number of Exchange Shares was determined based on the Black-Scholes value of the Exchange Warrants divided by $0.3101 per share, the closing
price of the Q/C Common Stock on the last trading day prior to execution of the Warrant Exchange Agreement. The Company paid no additional
consideration in the Warrant Exchange.
In addition, as majority
holder of Q/C’s Series H Convertible Preferred Stock (the “Q/C Series H Preferred Stock”), the Company consented under
the Warrant Exchange Agreement to an amendment to the Certificate of Designations of the Q/C Series H Preferred Stock that extends the
maturity date of the Q/C Series H Preferred Stock from March 2, 2027 to September 2, 2027 (the “Series H Amendment”). The
Company paid no consideration for the Series H Amendment.
Joshua N. Silverman, the
Company’s Chief Executive Officer and Chairman of the Board of Directors, serves as the Chief Executive Officer of Q/C. The Company
is also a holder of Q/C’s Series G Convertible Preferred Stock.
The Exchange Shares have
not been registered under the Securities Act of 1933, as amended. Pursuant to the Warrant Exchange Agreement, upon the Company’s
demand beginning 90 days after the Warrant Exchange, Q/C will be required to file a resale registration statement with the Securities
and Exchange Commission to register the Exchange Shares for resale within 30 days after receiving such demand.
The foregoing description
of the Warrant Exchange Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the
Warrant Exchange Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 2.01 Completion of Acquisition or Disposition
of Assets.
The information set forth
in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. |
|
Description |
| 10.1 |
|
Consent and Warrant Exchange Agreement, dated November 15, 2026, by and between Q/C Technologies, Inc. and PharmaCyte Biotech, Inc. |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| |
|
|
| |
PHARMACYTE BIOTECH, INC. |
| |
|
| Date: November 19, 2026 |
|
| |
|
|
| |
By: |
/s/ Joshua N. Silverman |
| |
Name: |
Joshua N. Silverman |
| |
Title: |
Chief Executive Officer and President |